Skip to main content

CHA₂DS₂-VASc Calculator

CHA₂DS₂-VASc Calculator

Stroke Risk Assessment in Atrial Fibrillation

Select the applicable clinical risk factors below. Age and female sex are included directly in the scoring criteria.

Clinical Risk Factors

Select only one age category. Age below 65 years receives zero age points. Female sex category is scored separately.

CHA₂DS₂-VASc Score

0
Clinical Interpretation

Anticoagulation Guidance

CHA₂DS₂-VA Score (2024 ESC)

CHA₂DS₂-VASc Scoring Reference

Risk FactorPoints
Congestive Heart Failure1
Hypertension1
Age ≥75 years2
Diabetes Mellitus1
Stroke / TIA / Thromboembolism2
Vascular Disease1
Age 65–74 years1
Female Sex Category1

Clinical Notes

  • Men: anticoagulation is recommended at CHA₂DS₂-VASc ≥2 and reasonable at 1 under the 2023 ACC/AHA guideline.
  • Women: anticoagulation is recommended at ≥3 and reasonable at 2. Female sex alone does not indicate anticoagulation.
  • 2024 ESC uses CHA₂DS₂-VA: anticoagulation should be considered at 1 and is recommended at ≥2.
  • Reassess stroke risk periodically as age and clinical risk factors change.
  • Bleeding risk should be assessed and modifiable factors corrected. A high bleeding-risk score alone should not automatically lead to withholding anticoagulation.
Medical Disclaimer: This calculator is an educational clinical decision-support tool. It does not replace individual clinical assessment or physician judgment. It does not calculate an exact annual stroke probability or determine anticoagulant dose. Patients with mechanical heart valves or moderate-to-severe rheumatic mitral stenosis require a separate anticoagulation approach.

References

  1. 2023 ACC/AHA/ACCP/HRS Guideline for Atrial Fibrillation. Read guideline
  2. 2024 ESC Guidelines for the Management of Atrial Fibrillation. Read guideline
Cardiology Education and Clinical Calculators
drmusmanjaved.com

Comments

Post a Comment

Drop your thoughts here, we would love to hear from you

Popular posts from this blog

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...
Post a Comment
Latest Posts »

𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚

 𝘼𝙣𝙩𝙞𝙘𝙤𝙖𝙜𝙪𝙡𝙖𝙩𝙞𝙤𝙣 𝘼𝙛𝙩𝙚𝙧 𝙎𝙩𝙧𝙤𝙠𝙚 in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.
1 comment
Latest Posts »

2025 ESC Guidelines on INR Targets in Mechanical Valves

  2025 ESC Guidelines on INR Targets in Mechanical Valves INR Targets in Patients With Mechanical Heart Valves Updated, guideline-oriented review Mechanical heart valves are inherently thrombogenic and require lifelong anticoagulation. Vitamin K antagonists, particularly warfarin, remain the standard therapy. The international normalized ratio (INR) is used to guide anticoagulation intensity and must be individualized based on valve type, valve position, and patient-related thromboembolic risk factors. Subtherapeutic INR increases the risk of valve thrombosis and systemic embolism, whereas excessive anticoagulation increases bleeding risk. Why INR control is critical Mechanical valves promote thrombosis due to non-physiological blood flow, high shear stress, and continuous contact between blood and artificial surfaces. These prothrombotic mechanisms persist for life. Direct oral anticoagulants are contraindicated in mechanical valves; therefore, VKAs remain mandatory. The goal of I...
Post a Comment
Latest Posts »